InsidersTradesSigma
Track the Lexicon Pharmaceuticals, INC. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Health Care sector, Lexicon Pharmaceuticals, INC. has recorded 95 reports. Market capitalisation: €1bn. The latest transaction was disclosed on 4 June 2026 (Levée d'options). Among the most active insiders: DEBBANE RAYMOND. The full history is free.
95
Insider Decl.
n/a
Thresholds
€119m
21 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Lexicon Pharmaceuticals, INC. Buy (bullish), based on 5 analysts. Average price target: US$3.77.
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,063 of 29,062 companies
36.6
score / 100
Value21
Quality53
FCF yld-6.7%
Earn yld-4.9%
EV/EBITDA·
ROE-40%
Gross mgn99%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 June 2026
Declarations95 total
89,312 shares0Common StockSEC:0001062822-26-000103:0
89,312 shares0Common StockSEC:0001062822-26-000104:0
89,312 shares0Common StockSEC:0001062822-26-000105:0
89,312 shares0Common StockSEC:0001062822-26-000102:0
27,697 sharesCommon StockSEC:0001062822-26-000041:0
67,090 sharesCommon StockSEC:0001062822-26-000040:0
35,790 sharesCommon StockSEC:0001062822-26-000039:0
14,000 sharesCommon StockSEC:0001062822-26-000038:0
24,674 sharesCommon StockSEC:0001062822-26-000037:0
33,457 sharesCommon StockSEC:0001062822-26-000036:0
160,237 sharesCommon StockSEC:0001062822-26-000035:0
503,263 sharesCommon StockSEC:0001062822-26-000034:0
2,000 shares@ US$1.490.1% of flowCommon StockSEC:0001062822-26-000033:0
Canonical exit: 26 May 2026 (T+90)
100,000 shares@ US$1.473.9% of flowCommon StockSEC:0001062822-26-000032:0
Canonical exit: 24 May 2026 (T+90)
50,000 shares@ US$1.43931.9% of flowCommon StockSEC:0001062822-26-000031:0
Canonical exit: 20 May 2026 (T+90)
41,289.58 shares@ US$65.00100.0% of flowSeries B Convertible Preferred StockSEC:0001193125-26-059599:0
57,952 shares@ US$1.30932.0% of flowCommon StockSEC:0001062822-26-000029:0
Canonical exit: 14 May 2026 (T+90)
18,553,846 shares@ US$1.30100.0% of flowCommon StockSEC:0001193125-26-037644:0
36,810 shares0Common StockSEC:0001127602-25-014145:0
36,810 shares0Common StockSEC:0001127602-25-014143:0
36,810 shares0Common StockSEC:0001127602-25-014146:0
36,810 shares0Common StockSEC:0001127602-25-014144:0
36,810 shares0Common StockSEC:0001127602-25-014140:0
36,810 shares0Common StockSEC:0001127602-25-014139:0
24,673 sharesCommon StockSEC:0001127602-25-007527:0
25 of 95 declarations
Acerca de Lexicon Pharmaceuticals, INC.
Lexicon Pharmaceuticals, INC. es una empresa biofarmacéutica centrada en el desarrollo de terapias innovadoras para enfermedades genéticas y metabólicas. Cotiza en NASDAQ bajo el símbolo LXRX.